Navigation Links
Phase III study shows everolimus delays tumor progression in hard-to-treat neuroendocrine tumors
Date:10/12/2010

The results of a large Phase-III clinical trial have shown that the drug everolimus delays tumor progression in patients with a hard-to-treat group of rare cancers that affect particular hormone-producing cells.

At the 35th Congress of the European Society for Medical Oncology (ESMO), Dr Marianne Pavel from Charit University in Berlin, Germany reported that everolimus improved progression-free survival by 5.1 months in patients with advanced neuroendocrine tumors.

Neuroendocrine tumors are slow-growing malignancies that originate from cells of the body's neuroendocrine system. These cells are found throughout the body in organs such as the gastrointestinal tract and the lungs. The tumors are mostly non-responsive to chemotherapy drugs. They affect less than five people in 100,000, and until now there have been few treatment options for inhibition of tumor growth.

In the new RADIANT-2 trial, researchers in several European countries and the USA treated 429 patients with progressing, well- or moderately-differentiated advanced neuroendocrine tumors with either everolimus plus a somatostatin analog called octreotide LAR, or placebo plus octreotide LAR.

All patients had a history of 'carcinoid' symptoms, meaning the tumors have been secreting excessive levels of amines, especially serotonin, leading to symptoms such as flushing and diarrhea. The tumor originated in the small intestine in about 50% of patients.

Overall, the median progression-free survival for patients given everolimus plus octreotide LAR was 16.4 months, significantly longer than the median 11.3 months for placebo plus octreotide LAR, Dr Pavel reported.

"This is the first Phase-III trial of the combination therapy with octreotide LAR and everolimus and it is the largest trial that has ever been done in this type of neuroendocrine tumors," Dr Pavel said. "When we designed the study, we tested for an improvement of at least 4.5 months compared t
'/>"/>

Contact: Vanessa Pavinato
media@esmo.org
European Society for Medical Oncology
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Front-of-package symbols and systems: IOM phase 1 report
2. Vaccine extends glioblastoma patients survival in phase II trial
3. Operation Unified Response: 3 phases of disaster care in Haiti
4. Aeras and Crucell announce Phase II clinical trial start in Kenya
5. Sickle cell treatment developed at LA BioMed enters Phase 3 clinical trial
6. Mass. General Hospital, Iacocca Foundation announce completion of Phase I diabetes trial
7. Late-stage ovarian cancer shows promise in 2-drug phase I trial
8. Late-stage ovarian cancer shows promise in two-drug phase I trial
9. Accumed Research Associates Expands Capabilities In Phase I and Bioequivalence Clinical Trials
10. Phase II study of an oral therapy for Gaucher disease yields positive results
11. New phase II study supports potential of gs-9450 as new treatment option for steatohepatitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2015)... Pismo Beach, CA (PRWEB) February 28, 2015 ... the needs of Central Coast area residents, recently announced ... Whitening System. It’s a treatment option for new ... patients kick off 2015 with a bright, white smile, ... the discounted price of $299, marked down from the ...
(Date:2/28/2015)... 28, 2015 Kaylie Corrigan, Outdoor Supervisor ... center , and current student obtaining her Masters degree ... a weekly forum in psychoeducation on substance use for ... AZ as part of her studies. , “Even though ... support and counseling at the high school and junior ...
(Date:2/28/2015)... The noted Friedman Dental Group of ... officially relaunched their website. The new version of the ... a new section about their team members. Potential and ... biographies of each Friedman Dental Group team member including ... designed to provide our patients with the opportunity to ...
(Date:2/28/2015)... (PRWEB) February 28, 2015 Javon ... recognizes Mercy Harvard Hospital as stroke capable by the ... brought via ambulance to Mercy Harvard Hospital. , The ... to indicate their ability to treat stroke according to ... allows ambulances transporting stroke patients to bypass hospitals not ...
(Date:2/28/2015)... Memphis, TN: MedixSafe has retracted a previous announcement ... reader named Guardian 2. The correct product name ... scanner that significantly increases the complexity of security ... scanner provides fast and easy access for both ... lockers with Vanguard technology tracks inventory by ...
Breaking Medicine News(10 mins):Health News:Pismo Beach Dentist Announces Special for Zoom! Teeth Whitening 2Health News:Staff at Arizona Drug Addiction Treatment Center Starts Teen Sobriety Support Group at Local High School 2Health News:Friedman Dental Group Announces Their Updated Website 2Health News:Mercy Harvard Hospital Recognized as Leader in Stroke Care - Javon Bea 2Health News:New Name Announced For Newest MedixSafe Readers – MedixSafe Vanguard 2
... Results from the landmark AIDS Treatment for Life ... more than 2,000 people living with HIV/AIDS (PLWHA), ... critical health-related conditions that may negatively impact patients, ... outcomes. The data suggested that while patients ...
... skin cancer melanoma appear different in Florida than ,from national ... black women but lower rates among Hispanic women, according to ... Dermatology, one of the JAMA/Archives journals. "In the ... that of any other cancer," the authors write as background ...
... Centre of Excellence in HIV/AIDS (BC-CfE) published an important ... The study strongly reinforces the view that the benefits ... of the virus to significantly preventing the transmission and ... standard treatment for HIV, HAART uses a combination of ...
... July 19, 2010 Kidney disease is a growing ... in the United States requiring dialysis treatments to replace ... particularly acute among African-Americans, whose rates of kidney disease ... As reported online this month by the journal ...
... By Jenifer Goodwin HealthDay Reporter , MONDAY, ... children can attest, youngsters with the disorder are often slower to ... new research shows. However, the good news from the ... doesn,t seem to suffer. Problems with eating can emerge as ...
... the best athletes, but a new study led by ... the use of minimally invasive arthroscopic surgery to treat ... undergo the procedure another opportunity to resume their sport ... researchers at Rush determined that 78 percent of athletes ...
Cached Medicine News:Health News:Global HIV/AIDS survey by IAPAC reveals critical gap in patient-physician conversations 2Health News:Global HIV/AIDS survey by IAPAC reveals critical gap in patient-physician conversations 3Health News:Global HIV/AIDS survey by IAPAC reveals critical gap in patient-physician conversations 4Health News:Global HIV/AIDS survey by IAPAC reveals critical gap in patient-physician conversations 5Health News:Global HIV/AIDS survey by IAPAC reveals critical gap in patient-physician conversations 6Health News:Melanoma rates among minorities in Florida differ from national trends 2Health News:HIV/AIDS treatment curbs spread of disease: UBC-BC CfE study 2Health News:HIV/AIDS treatment curbs spread of disease: UBC-BC CfE study 3Health News:Investigators identify gene associated with kidney disease in African-American population 2Health News:Investigators identify gene associated with kidney disease in African-American population 3Health News:Autistic Kids Often Fussier Eaters, but Nutrition OK 2Health News:Autistic Kids Often Fussier Eaters, but Nutrition OK 3Health News:Autistic Kids Often Fussier Eaters, but Nutrition OK 4Health News:New study finds arthroscopic hip surgery may fully restore function in athletes 2
(Date:2/27/2015)... 27, 2015 WuXi PharmaTech (Cayman) Inc. (NYSE: ... company serving the pharmaceutical, biotechnology, and medical device industries ... the United States , congratulates our ... the U.S. FDA for ibalizumab (TMB355). The FDA designates ... intended, alone or in combination with one or more ...
(Date:2/27/2015)... SUNNYVALE, Calif. , Feb. 27, 2015 /PRNewswire/ ... highlighted findings from a pre-clinical study published in ... Sciences ( www.pnas.org/cgi/doi/10.1073/pnas.1500712112 ) that showed when ... anti-PD-L1 antibody (a checkpoint inhibitor), suppression of tumor ... be achieved when treating certain hematologic cancers and ...
(Date:2/27/2015)... Feb. 27, 2015  Following a bipartisan vote ... moved H.R. 284, the Medicare DMEPOS Competitive Bidding ... for Homecare (AAHomecare) released a statement praising the ... pass the legislation. "Today,s mark-up of ... Ways and Means Committee is a critical step ...
Breaking Medicine Technology:WuXi Congratulates TaiMed Biologics on Receiving Breakthrough Therapy Designation from U.S. FDA 2In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 2In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 3In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 4In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 5In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 6In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 7In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 8In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 9Bidding Fix Takes Major Step Forward After Bipartisan Vote of House Ways and Means Committee 2
... INDIANAPOLIS, Oct. 4, 2011 Roche (SIX: RO, ROG; OTCQX: ... line in North America beyond physician offices and outpatient clinics ... for hospital and reference laboratories. The new line is expected ... subject to regulatory approval and other requirements. ...
... Eli Lilly and Company (NYSE: LLY ... achieving two of the company,s three environmental goals ahead of schedule. ... waste sent to landfills by about 50 percent and has reduced ... track to meet its energy goal. Lilly has improved the energy ...
Cached Medicine Technology:Roche to Expand Coagulation Testing Portfolio, Develop New Systems for Diagnostic Laboratories in US and Canada by 2014 2Lilly Improves Its Environmental Footprint in Business Operations and Helps Beautify Communities 2Lilly Improves Its Environmental Footprint in Business Operations and Helps Beautify Communities 3
... of Vision and Contrast Sensitivity. The ... and glare luminance levels for accurate ... with/without glare and background luminance Comply ... standards. All Light Levels Microprocessor Controlled ...
... profitability by reducing ... simple test,sequences that ... by ancillary office ... 5 minutes. New ...
Holladay Contract Acuity Test provides a more sensitive evaluation for testing visual functions than standard acuity charts....
Vectograms are the standard for vision training. They are available in fixed or variable,styles to accommodate unlimited base-in and base-out training. Each vectogram,includes one pair,of standard 3-...
Medicine Products: